Monocyte upregulation of podoplanin during early sepsis induces complement inhibitor release to protect liver function

Zhanli Xie, Bojing Shao, Christopher Hoover, Michael McDaniel, Jianhua Song, Miao Jiang, Zhenni Ma, Fei Yang, Jingjing Han, Xia Bai, Changgeng Ruan, and Lijun Xia

Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, NHC Key Laboratory of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University, Jiangsu, China. Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA. Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. Collaborative Innovation Center of Hematology and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China.

Introduction

Sepsis is a life-threatening organ dysfunction triggered by a dysregulated host response to infection (1). The incidence of sepsis is over 1.5 million cases annually in the United States (2), and approximately 18 million cases globally (3). Around 30% of patients with sepsis die of multiple organ dysfunction or failure in intensive care units (4). In sepsis, the liver is injured by inflammatory cytokines, microthrombi, and pathogens, leading to liver dysfunction and failure. The injured liver, in turn, facilitates dysfunction of other organs by enhancing inflammatory responses (5) and activating coagulation (6), whereby liver injury directly contributes to the death of patients with sepsis (7). Liver dysfunction occurs at an early stage of sepsis (8) and is associated with a poor prognosis (9); therefore, protecting liver function in early sepsis may prevent liver injury from progressing to liver failure, thus increasing patient survival. However, the mechanism underlying liver dysfunction in sepsis is poorly understood. Thus, few interventions to treat septic liver injury are available.

Platelets, the critical player in hemostasis and thrombosis, have essential functions in innate immunity (10) and tissue homeostasis (11). In sepsis, activated platelets secrete many proinflammatory and prothrombotic mediators that enhance organ injury (12). However, inhibition of platelet activation exhibits inconsistent therapeutic benefits in sepsis (13, 14). By contrast, platelet transfusion into nonbleeding sepsis patients shows a clinical benefit (15, 16) and reduces the mortality of E. coli–injected mice (17). The protective effect of platelet transfusion depends on platelet receptor C-type lectin-like receptor 2 (CLEC-2) (18), although its underlying mechanisms remain elusive.

CLEC-2 is a membrane receptor mainly expressed on platelets and primarily functions in the separation of lymphatic vessels from veins during development, maintenance of blood vessel integrity in some organs during inflammation, and promotion of tumor metastasis (19). Podoplanin, the only known endogenous
ligand for CLEC-2, is expressed on many cell types, including lymphatic endothelial cells, kidney podocytes, and lung alveolar epithelial cells (19). Blood cells and blood vessel endothelial cells in healthy animals do not express podoplanin (19), whereas resident macrophages in septic animals can express podoplanin (18). It is thought that CLEC-2 binding to podoplanin inhibits inflammatory cytokine generation in resident macrophages, by which septic animals are protected (18, 20). Inhibition of inflammation, however, has given disappointing results in clinical trials on sepsis management (21). Thus, the mechanism by which platelets and platelet CLEC-2 protect patients or animals with sepsis is unclear.

As a critical component of innate immunity, the complement system promotes cell lysis and leukocyte recruitment and phagocytosis, in addition to regulating coagulation and cell signaling. There are 3 pathways to activate the complement system: the classical, alternative, and lectin pathways, which converge at the central complement component C3. C3 is enzymatically processed into C3a and C3b, and the latter then cleaves C5 into C5a and C5b. Finally, C5b binds C6, C7, C8, and C9 to form the membrane attack complex (C5b-9). In sepsis, the complement system is activated by pathogens (22), and controlled complement activation benefits pathogen clearance (23). However, overactivation of the complement system causes organ damage (24). For example, uncontrolled complement activation injures heart function in a mouse sepsis model (25), whereas inhibition of C3 or C5 protects liver function in a primate model of E. coli sepsis (26). Thus, inhibition of complement activation may protect liver function in sepsis. However, the mechanism by which complement activation is autonomously controlled in sepsis is not well known.

Here, we report that platelet CLEC-2 protects liver function in a mouse model of E. coli–induced sepsis. In early sepsis, circulating monocytes expressed podoplanin, which bound to CLEC-2 and induced release of complement inhibitors from platelets. The released complement inhibitors protected the liver from complement attack in early sepsis and reduced subsequent inflammation in the liver. Our findings suggest a potentially novel mechanism by which platelets protect liver function during early sepsis and an important function of platelets in inhibiting complement activation.

Results

Platelet CLEC-2 deficiency enhances liver dysfunction in early sepsis. We generated platelet-specific Clec-2−/− mice (Clec-2fl/fl Pf4-Cre) by breeding Clec-2fl/fl mice with Pf4-Cre transgenic mice, which express Cre recombinase specifically in megakaryocytes and platelets (27). To explore whether platelet CLEC-2 protects liver function at the early stage of sepsis, we used Plt Clec2−/− mice and the WT littermates. Deletion of platelet CLEC-2 reduced the blood platelet count in male mice, but not female mice, and had no effects on body weight (Supplemental Figure 1, A–C; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.134749DS1). Thus, only female mice were used in vivo studies. Sepsis was generated in mice by peritoneal injection of a half-lethal dose of E. coli (2 × 10^7 CFU/mouse), which presented a slow progression of sepsis, allowing us to detect the alteration of liver function. Challenge with E. coli induced similar thrombocytopenia and loss of body weight in WT and Plt Clec2−/− mice (Supplemental Figure 2, A and B). The half-lethal dose of E. coli caused the death of around 20% of WT mice and 70% of Plt Clec2−/− mice at 100 hours after infection (Figure 1A). Thus, platelet CLEC-2 played a protective role when the mice experienced bacterial infection.

We assessed liver function by detecting the serum levels of alanine transferase (ALT), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and bilirubin, as well as by examining liver histology. All serum markers of liver function in both WT mice and Plt Clec2−/− mice started to increase dramatically at 1 hour after E. coli infection (Figure 1, B–E). Liver function markers in WT mice reached a plateau at 4 to 8 hours after infection (Figure 1, B–E). Compared with WT mice, Plt Clec2−/− mice had significantly higher serum levels of these markers at 8 hours after E. coli injection (Figure 1, B–E). We further examined the liver histology and found that loss of platelet CLEC-2 did not alter the liver histology in healthy mice (Figure 1F). There were considerable histological changes in the liver at 8 hours after E. coli infection, including the destruction of hepatic lobules, cytoplasmic vacuolization, sinusoid obstruction, necrosis, and inflammatory cell infiltration (Figure 1F). Here, ballooning degeneration, a form of apoptosis, in the liver was quantified, and platelet CLEC-2 deficiency significantly increased this injury in the liver of infected mice (Figure 1F). These results indicate that deficiency of platelet CLEC-2 exacerbated liver dysfunction in early sepsis.

Platelet CLEC-2 deficiency increases liver inflammation in early sepsis, which is independent of podoplanin-mediated inhibition of cytokine generation in resident macrophages. To study the role of platelet CLEC-2 in...
Inflammation, we examined inflammation responses in the septic liver. WT and Plt Clec2−/− liver tissues were collected at different time points after E. coli infection, and the expression of TNF-α and IL-1β was analyzed using quantitative PCR. Compared with the liver from healthy mice, the expression of TNF-α and IL-1β in the liver from WT and Plt Clec2−/− mice began to increase at 2 hours following E. coli infection (Figure 2, A and C). At 8 hours after E. coli infection, the expression of TNF-α and IL-1β in the liver from Plt Clec2−/− mice was significantly higher than that in the liver of WT mice (Figure 2, A and C). TNF-α and IL-1β staining were performed using cryosections of liver tissues collected at 8 hours.

---

Figure 1. Platelet CLEC-2 deficiency enhances liver dysfunction in early sepsis. (A) Survival rate of mice analyzed using a log-rank test. n = 15 mice/group. Data were representative of 3 independent experiments. (B–E) Blood chemistry: ALT, LDH, bilirubin, and AST. (F) Representative images and quantification of injuries of H&E-stained liver sections collected from mice at 8 hours after i.p. injection of saline or E. coli. Data are mean ± SD. n = 6 mice/group. #P < 0.05, comparing the sample at 0 hours of E. coli injection with samples at other time points after E. coli infection. *P < 0.05; **P < 0.01. Data were analyzed using 1-way ANOVA followed by Tukey’s test for multiple groups and were representative of 3 independent experiments. Scale bar: 400 μm.
after *E. coli* infection based on published methods (28–30), revealing that CLEC-2 deficiency increased the expression of TNF-α and IL-1β in the liver of infected mice, which partially overlapped with macrophages (F4/80-positive) (Figure 2, B and D; and Supplemental Figure 3, A and B). Thus, platelet CLEC-2 deficiency enhanced inflammation in the liver in early sepsis.

Podoplanin is expressed in resident macrophages in the lung of septic mice (20) and cultured macrophages upon lipopolysaccharide stimulation (31), the ligand for CLEC-2 (19). CLEC-2 binding to podoplanin inhibits the generation of inflammatory cytokines in lung macrophages (20). To determine whether podoplanin is expressed in the liver, liver cryosections from *E. coli*-infected WT mice were stained with antibodies against podoplanin and macrophages. As the positive control, the kidneys, which express podoplanin on podocytes in glomeruli (19), showed strong podoplanin staining (Supplemental Figure 4A). However, there was only weak staining of podoplanin in the WT liver after *E. coli* injection, which was not colocalized with liver macrophages (Figure 2E and Supplemental Figure 4B). We then examined podoplanin expression on neutrophils, which were the first immune cells to infiltrate the inflamed tissue. An increased number of Ly6G-positive neutrophils was found in the WT liver after *E. coli* injection, but these infiltrated neutrophils did not express podoplanin (Supplemental Figure 4C). Further confocal imaging revealed more CD41-positive platelets in the liver after *E. coli* injection; however, these platelets appeared not to interact with podoplanin at the examined time point (Supplemental Figure 5). Thus, our results show that *E. coli* infection did not induce podoplanin expression on the liver macrophages and that platelets did not interact with podoplanin in the liver during early sepsis. These data indicate that increased inflammation in the liver of Plt Clec2−/− mice in early sepsis was not due to a lack of podoplanin-dependent inhibition of the macrophage cytokine generation.

**Platelet CLEC-2 deficiency increases complement activation and liver attack in early sepsis.** Because the complement system plays a key role in the pathogenesis of sepsis (22), we asked whether platelet CLEC-2 is involved in complement activation in early sepsis. First, we validated assays (Supplemental Figure 6) for measuring complement activation products, including C3a, C5a, and C5b-9. Then the activated complement products in plasma from *E. coli*-infected mice were measured. The plasma levels of C3a, C5a, and C5b-9 were elevated at 1 hour after *E. coli* infection, and reached a plateau at 4 hours after infection in both WT and Plt Clec2−/− mice (Figure 3, A–C). Interestingly, the plasma levels of C3a and C5a in Plt Clec2−/− mice were significantly higher than those in WT mice by 2 hours after *E. coli* infection, whereas the plasma level of C5b-9 in Plt Clec2−/− mice was higher only at 4 hours after infection (Figure 3, A–C). Thus, loss of platelet CLEC-2 increased complement activation in early sepsis.

We then detected the complement attack in the liver by staining C5b-9 on cryosections. Compared with the liver of saline-injected mice, the liver from mice infected with *E. coli* for 8 hours showed a positive staining for C5b-9, which was stronger in Plt Clec2−/− mice (Figure 3D and Supplemental Figure 7). C5b-9 staining was largely colocalized with F4/80-positive macrophages (Figure 3D and Supplemental Figure 7), suggesting that complement attacks macrophages as well as other types of liver cells. Meanwhile, *E. coli* infection caused increased cell apoptosis in the liver of Plt Clec2−/− mice compared with WT mice, as demonstrated by TUNEL staining (Figure 3E and Supplemental Figure 8).

**CLEC-2 deficiency reduces release of complement inhibitors from platelets in early sepsis.** Platelet α-granules contain complement inhibitors C1-INH (32), clusterin (33), and factor H (34). To test whether released α-granule contents inhibit complement activation, we measured the plasma levels of complement inhibitors in septic mice. The plasma levels of C1-INH, clusterin, and factor H in WT mice started to increase at 1 hour after *E. coli* infection and reached a plateau around 2–4 hours after infection (Figure 4, A–C). Surprisingly, the plasma levels of these inhibitors in Plt Clec2−/− mice were lower than those in WT mice at multiple time points (Figure 4, A–C). Increased plasma levels of platelet factor 4 (PF4) and P selectin, components of platelet α-granules, and P selectin on the platelet surface indicated platelet activation and release. We found that changes in these parameters in WT mice and Plt Clec2−/− mice after *E. coli* infection correlated with the alteration of complement inhibitors at early time points after *E. coli* injection (Figure 4, D–F). By contrast, the levels of ATP, which is a component of the platelet-dense granule, in platelets of WT and CLEC-2–deficient mice were comparable (Figure 4G). The plasma level of C1-INH, but not that of clusterin and factor H, increased mildly in Plt Clec2−/− mice 8 hours after *E. coli* injection (Supplemental Figure 9, A–C), whereas the plasma level of PF4 decreased 8 hours after infection (Supplemental Figure 9D). These results indicate that complement inhibitors were primarily released from platelet α-granules upon activation during early sepsis.
and at later time points, cell sources other than platelets may have also contributed to the release of some inhibitors such as C1-INH. Interaction of podoplanin and CLEC-2 is known to induce release of platelet α-granules; thus, our data indicate that CLEC-2 deficiency impaired the release of platelet α-granules in early sepsis.
Circulating monocytes in early sepsis express podoplanin that binds to platelet CLEC-2 and induces release of complement inhibitors from platelets. Macrophages in the lungs of septic mice express podoplanin (20), so we asked whether circulating monocytes express podoplanin to bind platelet CLEC-2. Blood was collected from mice before and after *E. coli* infection, and expression of podoplanin on monocytes was detected by flow cytometry. Ly6C and CD11b double-positive cells were defined as monocytes (Supplemental Figure 10). In healthy animals, podoplanin-positive monocytes were negligible (Figure 5A). Infection with *E. coli* increased the percentages of podoplanin-positive monocytes to around 15% and 35% at 0.5 hour and 1 hour, respectively (Figure 5A). The percentage of podoplanin-positive monocytes declined at 2 hours and 4 hours after infection (Figure 5A). Monocytes in Plt Clec2−/− mice showed a similar profile of podoplanin expression as those in WT mice (Figure 5A), indicating that podoplanin expression on monocytes in the septic mice was independent of platelet CLEC-2.
Further flow cytometry analysis showed that *E. coli* infection increased platelet-bound monocytes in the blood of WT mice relative to its basal level (Figure 5B and Supplemental Figure 11), indicating that podoplanin on blood monocytes interacts with platelet CLEC-2 in early sepsis to form platelet and monocyte aggregates. At 1 hour and 8 hours after *E. coli* infection, there were more aggregates in WT mice than *Plt Clec2–/–* mice (Figure 5B), suggesting more platelet activation in WT mice at these time points. We then confirmed the effect of podoplanin binding on the release of complement inhibitors from platelets. Incubation of isolated WT platelets with recombinant podoplanin, but not the vehicle control, rapidly induced secretion of C1-INH in a dose-dependent manner (Supplemental Figure 12, A and B). The selected dose of podoplanin caused secretion of PF4, C1-INH, clusterin, and factor H from WT platelets but not *Clec2–/–* platelets (Figure 5, C–F). Thus, podoplanin binding induced CLEC-2–dependent release of complement inhibitors from platelet α-granules.

Myeloid podoplanin deficiency reduces plasma levels of complement inhibitors and enhances liver dysfunction in early sepsis. To confirm the role of monocyte podoplanin in complement inhibition and liver protection in sepsis, we used LysM *Pdpn–/–* mice that had a normal platelet count in the peripheral blood (Supplemental Figure 13A). *E. coli* injection induced expression of podoplanin in circulating monocytes of WT but not LysM *Pdpn–/–* mice (Supplemental Figure 13, B–E), confirming the deletion of podoplanin in blood monocytes. Infection with a half-lethal dose of *E. coli* caused a higher mortality in LysM
Pdpn−/− mice (Figure 6A). The serum levels of LDH, bilirubin, ALT, and AST in LysM Pdpn−/− mice were higher than those in WT mice at 8 hours after *E. coli* infection (Figure 6, B–E), whereas the plasma levels of C1-INH, factor H, and clusterin in LysM Pdpn−/− mice were lower than those in WT mice at 1 hour and/or 2 hours after *E. coli* infection (Figure 6, F–H). Consequently, the plasma levels of C5a, C3a, and C5b-9 in LysM Pdpn−/− mice were higher than those in WT mice after *E. coli* infection (Figure 7, A–C). Thus, LysM Pdpn−/− mice recapitulated the phenotype of Plt Clec2−/− mice. These results indicate that interaction between monocyte podoplanin and platelet CLEC-2 is important in complement activation–dependent liver dysfunction in early sepsis.

**Figure 5. Podoplanin expressed on circulating monocytes binds to CLEC-2 and induces platelet release of complement inhibitors in early sepsis.** (A) Podoplanin expression on monocytes and (B) monocyte–platelet aggregates from peripheral blood of mice with or without *E. coli* injection were analyzed by flow cytometry. The platelet-monocyte complex was shown as the percentage of total monocytes. (C–F) Levels of PF4, C1-INH, clusterin, and factor H released from WT and Clec2−/− platelets incubated with saline or recombinant podoplanin for 2 hours at 37°C. Data represent mean ± SD, n = 6 mice/group. *P < 0.05, comparing the sample at 0 hours of *E. coli* injection with samples at other time points after *E. coli* infection. **P < 0.01. Data were analyzed using 1-way ANOVA followed by Tukey’s test for multiple groups and were representative of 3 independent experiments.

**Discussion**

We have shown that platelets protect liver function in a mouse model of *E. coli* sepsis by inhibiting complement activation. Circulating monocytes expressed podoplanin, which bound to CLEC-2 and induced

*insight.jci.org*  https://doi.org/10.1172/jci.insight.134749
secretion of complement inhibitors from platelets in early sepsis. These inhibitors reduced complement activation in the liver and consequently ameliorated liver dysfunction.

Septic liver injury progresses from hepatocellular dysfunction to liver failure. As an early sign of sepsis, liver dysfunction occurs within a couple of hours in a mouse sepsis model and within 24 hours in patients after diagnosis (8). Inflammation, coagulation, and complement cross-interact with each other and contribute to liver injury differentially at the different stages of sepsis. Inhibition of complement activation reduces coagulation activation and ameliorates systemic inflammatory responses within 24 hours in a primate model of E. coli sepsis, which protects liver function as a consequence (26). Uncontrolled complement activation causes cell death and organ damage in sepsis (24). However, it is unclear how complement activation is controlled autonomously in sepsis. Our results showed that platelets were a major source of complement inhibitors in early sepsis. Released complement inhibitors from platelets protected organs in septic animals from complement attack and complement-induced inflammation. These results not only are consistent with a primate study that shows inhibition of complement C3 and C5 protects liver function (35) but also provide mechanistic insights into the pathological consequences of the activated complement in early sepsis.

Figure 6. Myeloid podoplanin deficiency reduces plasma levels of complement inhibitors and exacerbates liver dysfunction in early sepsis. (A) The survival rate of WT and LysM Pdpn−/− mice with or without E. coli infection. n = 15 mice/group. Data were analyzed using a log-rank test and representative of 3 independent experiments. (B–H) Plasma levels of liver enzymes or platelet complement inhibitors of mice with or without E. coli injection. Data represent mean ± SD; n = 6 mice/group. # P < 0.05, comparing the sample at 0 hours of E. coli injection with samples at other time points after E. coli infection. * P < 0.05. ** P < 0.01. Data were analyzed using 1-way ANOVA followed by Tukey’s test for multiple groups and were representative of 3 independent experiments.
Our results showed that liver macrophages including the Kupffer cells of healthy mice and mice at the early stage of *E. coli* sepsis did not express podoplanin. This is consistent with previous reports that podoplanin is only expressed on lymphatic endothelial cells, mesothelial cells (36), and some progenitor cells (37) in the liver after prolonged stimulations, such as CCL4 administration and peritoneal dialysis (37, 38).

A recent study shows that podoplanin is expressed by multiple macrophage populations in the liver during *Salmonella* Typhimurium infection (39). However, podoplanin expression in the *Salmonella* Typhimurium infection model occurs mainly around day 7 of infection, which is much later than the stage we focused on in the current study. Macrophages are highly heterogeneous in terms of their functions and origins. At day 7 of infection, some podoplanin-positive macrophages may be derived from infiltrated circulating monocytes. In addition, different types of infection may account for different podoplanin expression patterns of macrophages in response to inflammation.

The role of platelets in the pathogenesis of sepsis is unclear. In a canonical model, activated platelets promote thrombosis and inflammation, facilitating organ injury in sepsis (40–42). However, platelet transfusion (15–17), but not platelet antagonists (13, 14), shows beneficial effects in sepsis management. It is thought that platelet transfusion protects septic animals by inhibiting inflammatory cytokine generation (17, 18); however, antiinflammation does not benefit the therapy of patients with sepsis (21). Thus, reduced inflammatory responses may not be the major contributor for the protective effect of platelet transfusion. Our studies demonstrated that platelets are a major resource of complement inhibitors in early sepsis. Injection of complement inhibitors into septic mice rescued liver function and reduced inflammation in the liver, indicating that supplementation of complement inhibitors was a major protective factor of platelet transfusion in sepsis. There was a modest increase of complement inhibitors in septic Plt Clec-2/− mice, suggesting podoplanin-dependent platelet release may not be the only source for complement inhibitors. Cell types such as monocytes (43), endothelial cells (44), and liver parenchymal cells (45) can synthesize C1-INH (46). Nevertheless, substantial reduction of the plasma levels of complement inhibitors in Plt Clec-2/− mice indicated that podoplanin-induced platelet release was a primary source for the complement inhibitors in early sepsis. Our results also suggest that the inconsistent effects of platelet antagonists in sepsis treatment may be due to the blockade of platelet activation and the release of complement inhibitors. Podoplanin binding to CLEC-2 activates platelets and promotes the release of platelet granules (47–49). This finding agrees with previous reports that formation of platelet-monocyte aggregates is an early phenomenon in sepsis progression (50, 51). Thus, CLEC-2–dependent platelet activation and granule release occur in the blood during early sepsis mainly through the interaction with podoplanin on monocytes.

In summary, platelets are an important source of complement inhibitors and protect liver function in early sepsis by inhibiting complement activation. We suggest a potentially novel mechanism underlying the protection of liver function in early sepsis.
**Methods**

Reagents. *E. coli* (ATCC25922) was a gift from Yi Wu (Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China). ELISA kits to detect mouse C5a (ELM-CCC5a-1) (52) and P selectin (ELM-Pselectin1) were purchased from Raybio. ELISA kits for C3a (MBS268280) (53) and C5b-9 (MBS776999) (54) were purchased from MyBioSource. ELISA kit for factor H was from Cusbio (CSB-E08933m) (55). ELISA kit for C1-INH was from Novus (NBP2-70029). ELISA kits for clusterin (ab199079) (56) and PF4 (ab100735) (57) were from Abcam. ApopTag fluorescein in situ apoptosis detection kit (S7110) was purchased from Millipore. Recombinant mouse podoplanin-Fc chimera protein (3244-PL-050) was from R&D Systems, Bio-Techne. Chicken polyclonal anti-albumin antibody (ab106582), rat monoclonal anti-F4/80 (ab6640), rabbit polyclonal anti–C5b-9 antibody (ab55811), rabbit polyclonal anti–TNF-α antibody (ab6671), rabbit polyclonal anti–IL-1β antibody (ab2105), Syrian hamster monoclonal anti-podoplanin antibody (ab11936), Alexa Fluor 405–conjugated goat anti-chicken IgY (ab175674), Alexa Fluor 594–conjugated goat anti-rat IgG (ab150160), Alexa Fluor 647–conjugated donkey anti-rabbit IgG (ab150075), and Alexa Fluor 647–conjugated goat anti-Syrian hamster IgG (ab180117) were purchased from Abcam. PerCP anti-mouse CD11b antibody (clone: M1/70) and phycoerythrin (PE) anti-mouse Ly6C antibody (clone: HK1.4) were from BioLegend. FITC anti-mouse podoplanin antibody (clone: 8.1.1) and FITC anti-mouse CD41 antibody (clone: MWReg30) were from eBioscience, Thermo Fisher Scientific. Allophycocyanin-conjugated anti-CD11b (17-0112-81) and PE-labeled antibodies, including anti-B220 (12-0452-81), anti-CD49b (12-5971-63), anti-NK1.1 (12-5921-81), and anti-Ly6G (12-9668-82), were from eBioscience, Thermo Fisher Scientific. PE-labeled anti-CD90 (MA5-17749) was from Invitrogen, Thermo Fisher Scientific. Anti-PE microbeads (130-048-801) were from Miltenyi Biotec. PE anti-mouse CD41 antibody (558040) was from BD Biosciences. Polybead microspheres 3.00 μm (17134-15) were from Polysciences.

Mice and sepsis models. C57BL/6J (B6, CD45.2) mice, Ptf4-Cre mice, and LysM-Cre mice were purchased from The Jackson Laboratory. Clec-2–floxed mice (Clec-2fl/fl) and podoplanin–floxed mice (Pdpnfl/fl) were generated as previously described (27). Platelet CLEC-2–deficient mice (Pit Clec2−−) were generated by crossing Clec-2fl/fl mice with Ptf4-Cre mice (27). Myeloid cell podoplanin–deficient mice (LysM Pdpn−−) were generated by crossing Pdpnfl/fl mice with LysM-Cre mice.
Plt Clec2−/− or LysM Pdpn−/− and WT littersmates at 8 weeks old were i.p. injected with a half-lethal dose of E. coli (2 × 10⁶ CFU/mouse). At different time points after injection, animals were weighed, and blood and tissues were collected. Animal survival was observed for 100 hours.

Platelet count with flow cytometry. Peripheral blood was collected and counted by flow cytometry using PE anti-mouse CD41 antibodies and Polybead microspheres 3.00 μm (Polysciences) as internal standards.

Blood chemistry. Blood was collected by cardiac puncture without anticoagulant, and serum was isolated by centrifugation at 2000 g. Serum bilirubin, AST, LDH, and ALT were measured by an automatic chemistry analyzer (Roche Cobas 8000).

Histopathology. Mouse liver tissues were fixed, processed, and embedded in paraffin. After removal of the paraffin, tissues were sectioned (5 μm/section) and stained with H&E (Beyotime Products). Slides were imaged with a Leica DM2000 microscope.

Quantitative PCR. Total RNA from mouse livers was extracted with the RNeasy Plus Mini Kit (QIAGEN). cDNA was prepared from 1.8 μg RNA in 20 μL H₂O using the High Capacity RNA-to-cDNA Kit (Life Technologies). The levels of TNF-α and IL-1β cDNA were quantitated by quantitative PCR using iQ SYBR Green Supermix (Bio-Rad) in 20-μL reactions under conditions of 1 cycle at 50°C for 2 minutes, 1 cycle at 95°C for 2 minutes, and 40 cycles at 95°C for 15 seconds and 60°C for 35 seconds. The primers were CTACTCCAGGTCTCTTTCAA and GCAGAGAGGGAGGTGACTTTC for TNF-α; TGT-GTCTTTCCGTGGACCT and CAGCTCATATGGGTCCGACA for IL-1β (58). Actin cDNA was used as internal control. Primers for actin were GTGCTATGTTGCTCTAGACTTCG and ATGCCACAG-GATTTCCATACCC (58). Data from at least 3 independent sets were calculated as mean ± SD.

Confocal analysis of the septic liver. Livers of septic mice were collected at indicated time points after infection with E. coli and fixed with 4% paraformaldehyde. After cryopreservation with 20% sucrose, livers and other organs were embedded with OCT compound (Tissue-Tek, Sakura Finetek). Cryosections of 15-μm thickness were prepared and stained with antibodies against albumin, macrophages (F4/80), CD11b, TNF-α, or podoplanin. Samples were imaged with a confocal microscope (TCSSP8, Leica).

Measurement of blood complement components and complement inhibitors. Blood was collected from the retro-orbital plexus at different time points after E. coli infection. The plasma levels of C3a, C5a, C5b-9, C1-INH, factor H, and clusterin were measured by ELISA kits following the manufacturer’s instructions. The plasma level of PF4 was measured with ELISA kits as controls for platelet granule secretion. ATP release tracings from the same blood samples were performed with the Lumi-Aggregometer model 700 (Chrono-log).

TUNEL assay. For in situ analysis of apoptotic cell death in the septic liver, livers were immersion fixed in 10% buffered formalin and embedded in paraffin. After tissues were sectioned and deparaffinized, sections were stained using the TUNEL kit (MilliporeSigma). Total cells with FITC-labeled apoptotic nuclei were counted and analyzed under a fluorescence microscope.

Analysis of platelet-monocyte aggregates and monocytic expression of podoplanin. Anticoagulated mouse blood was collected via cardiac puncture and was diluted (1:1) with Dulbecco’s PBS (DPBS) without calcium and magnesium. After lysis of red blood cells, total white blood cells were stained with fluorophore-tagged antibodies. Platelet-monocyte aggregate and podoplanin expression on monocytes were analyzed with FACSCalibur (Beckman Coulter FC500). Specifically, the white blood cell population was selected with size scatter. In the white cell population, cells that were double positive for CD11b and Ly6C were defined as circulating monocytes, and podoplanin expression in this population was measured. In monocytes, cells that were triple positive for CD11b, Ly6C, and CD41 were defined as the platelet-monocyte aggregate. The complexes show as the percentage of all monocytes of double-positive CD11b and Ly6C.

Complement inhibitor secretion from platelets in vitro. Mouse blood was collected via cardiac puncture with a 21-G needle and a syringe containing 200 μL of acid citrate dextrose (ACD: 2.5% trisodium citrate, 2.0% d-glucose, 1.5% citric acid), followed by 1:1 dilution with modified Tyrode’s buffer (134 mM NaCl, 0.34 mM Na₂HPO₄, 2.9 mM KCl, 12 mM NaHCO₃, 20 mM HEPES at pH 7.0, 5 mM glucose, 0.35% BSA). Blood was centrifuged at 100 g for 8 minutes, and the platelet-rich plasma (PRP) was transferred to a new tube. PRP was centrifuged at 800 g for 10 minutes at room temperature (RT) to obtain a platelet pellet. The platelet pellet was washed twice in 1 mL modified Tyrode’s buffer and resuspended with modified Tyrode’s buffer. Washed platelets were incubated with different doses of podoplanin for different times; then platelets were removed by centrifugation at 800 g for 10 minutes. Complement inhibitors, PF4, and P selectin in the supernatant were measured with ELISA kits.

Rescue of liver function in septic mice with secreted complement inhibitors from platelets. WT and CLEC-2–deficient platelets were incubated with 10 μg/mL recombinant podoplanin-Fc chimera for 2 hours at 37°C.
After spinning down platelets, the supernatant was incubated with protein A/G agarose beads at RT for 1 hour to remove podoplanin. The concentration of C1-INH was measured with an ELISA kit, and the removal of podoplanin was confirmed with Western blot. Platelet CLEC-2–deficient mice at 8 weeks old were i.p. injected with a half-lethal dose of *E. coli*. At 1 hour after infection, the supernatant from podoplanin-pretreated WT and CLEC-2–deficient platelets was i.p. injected into septic mice. At 8 hours after infection, blood and livers were collected for the measurement of liver function and complement activation.

Detection of complement activation by zymosan-activated serum. To prepare zymosan-activated serum, 0 mg, 2.5 mg, 10 mg, 40 mg, and 160 mg zymosan was diluted in 1 mL distilled water. The solution was centrifuged at 300 g for 5 minutes at RT, and the pellet was washed with DPBS. After a further centrifugation step, the supernatant was removed, and the zymosan pellet was resuspended in 20 mL DPBS. A total of 1 mL of the zymosan DPBS stock solution was centrifuged (350 g, 5 minutes, RT) and the supernatant was removed. For serum activation, the zymosan pellet was resuspended in 200 μL serum to a final concentration of 0 mg, 0.625 mg, 2.5 mg, 10 mg, and 40 mg zymosan/mL serum and incubated at 37°C for 30 minutes to activate the complement cascade. The serum levels of C3a, C5a, and C5b-9 were measured by ELISA kits (MyBioSource).

Statistics. Data are expressed as mean ± SD from at least 3 independent experiments unless otherwise indicated. Data were analyzed using GraphPad Prism 5. For parametric comparisons, 1-way ANOVA followed by Tukey’s test for multiple groups and a 2-tailed Student’s *t* test for 2 groups were used. Survival curves were generated, and comparisons of median survival were performed using a log-rank test. A *P* value less than 0.05 was considered statistically significant.

Study approval. Animal studies were conducted with protocols approved by the Institutional Animal Care and Use Committee of Soochow University.

Author contributions
ZX, BS, and LX conceived the project, designed experiments, analyzed the data, and wrote the manuscript. CR provided critical advice and analyzed the data. ZX, BS, CH, MM, JS, MJ, ZM, FY, JH, and XB performed experiments.

Acknowledgments
This study was supported by the Jiangsu Provincial Key Medical Center (YXZXA2016002), the Priority Academic Program Development of Jiangsu Higher Education Institutions, National Natural Science Foundation of China (81520108005 and 81800128), the Natural Science Foundation of Jiangsu Province (BK20170361), the NIH (HL128390), and the Oklahoma Medical Research Foundation.

Address correspondence to: Lijun Xia, Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, Oklahoma 73104, USA. Phone: 405.271.7892; Email: lijun-xia@omrf.org.

1. Singer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315(8):801–810.
2. Seymour CW, et al. Time to treatment and mortality during mandated emergency care for sepsis. *N Engl J Med*. 2017;376(23):2235–2244.
3. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. *Nat Rev Immunol*. 2006;6(11):813–822.
4. Angus DC, van der Poll T. Severe sepsis and septic shock. *N Engl J Med*. 2013;369(9):840–851.
5. Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. *Hepatology*. 2009;50(6):2022–2033.
6. Okamoto K, Tamura T, Sawatsuhashi Y. Sepsis and disseminated intravascular coagulation. *J Intensive Care*. 2016;4:23.
7. Canabal JM, Kramer DJ. Management of sepsis in patients with liver failure. *Curr Opin Crit Care*. 2008;14(2):189–197.
8. Recknagel P, et al. Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis. *PLoS Med*. 2012;9(11):e1001338.
9. Kramer L, Jordan B, Druml W, Bauer P, Metnitz PG, Austrian Epidemiologic Study on Intensive Care, ASDI Study Group. Incidence and prognosis of early hepatic dysfunction in critically ill patients—a prospective multicenter study. *Crit Care Med*. 2007;35(4):1099–1104.
10. Deppermann C, Kubes P. Platelets and infection. *Semin Immunol*. 2016;28(6):536–545.
11. Kurokawa T, Zheng YW, Ohkohchi N. Novel functions of platelets in the liver. *J Gastroenterol Hepatol*. 2016;31(4):745–751.
12. Suresh B, et al. α-Toxin induces platelet aggregation and liver injury during Staphylococcus aureus sepsis. *Cell Host Microbe*. 2018;24(2):271–284.e3.
49. Séverin S, et al. Syk-dependent phosphorylation of CLEC-2: a novel mechanism of hem-immunoreceptor tyrosine-based activation motif signaling. *J Biol Chem*. 2011;286(6):4107–4116.

50. Gros A, Ollivier V, Ho-Tin-Noé B. Platelets in inflammation: regulation of leukocyte activities and vascular repair. *Front Immunol*. 2014;5:678.

51. Kral JB, Schnorrmaier WC, Salzmann M, Assinger A. Platelet interaction with innate immune cells. *Transfus Med Hemother*. 2016;43(2):78–88.

52. Kang SA, et al. Safety evaluation of intravenously administered mono-thioated aptamer against E-selectin in mice. *Toxicol Appl Pharmacol*. 2015;287(1):86–92.

53. Cipolla E, et al. IL-17A deficiency mitigates bleomycin-induced complement activation during lung fibrosis. *FASEB J*. 2017;31(12):5543–5556.

54. Li WW, et al. Autoimmunity contributes to nociceptive sensitization in a mouse model of complex regional pain syndrome. *Pain*. 2014;155(11):2377–2389.

55. Xu J, et al. Function of complement factor H and imaging of small molecules by MALDI-MSI in a methamphetamine behavioral sensitization model. *Behav Brain Res*. 2019;364:233–244.

56. de Retana SF, et al. Peripheral administration of human recombinant ApoJ/clusterin modulates brain beta-amyloid levels in APP23 mice. *Alzheimers Res Ther*. 2019;11(1):42.

57. Petzold T, et al. β1 integrin-mediated signals are required for platelet granule secretion and hemostasis in mouse. *Blood*. 2013;122(15):2723–2731.

58. Yang A, Xie Z, Wang B, Colman RW, Dai J, Wu Y. An essential role of high-molecular-weight kininogen in endotoxemia. *J Exp Med*. 2017;214(9):2649–2670.